SQUIRE enrolled a range of patients with metastatic squamous NSCLC1-3
SQUIRE: Demographics and baseline characteristics1-3
*One patient with ECOG PS 3 was accidentally enrolled and randomly assigned to the gemcitabine and cisplatin arm; this patient did not receive treatment.
† Nonsmokers included patients with fewer than 100 cigarettes lifetime; ex-light smokers ceased smoking at least 15 years before day 1 of study treatment and 10 pack-years or fewer; smokers included all others.
- SQUIRE included patients with ECOG PS 0, 1, and 21
- 91% of patients had metastases to 2 or more sites (including brain, bone, liver, lung, lymph nodes, peritoneal, pleural, skin, soft tissue, or other)1,2
NSCLC=non-small cell lung cancer; ECOG=Eastern Cooperative Oncology Group; PS=performance status.
References: 1. Portrazza (necitumumab) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015. 2. Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015;16(7):763-774. 3. Data on file. Lilly Research Laboratories (ONC20150421c).
Lilly PatientOne Co-pay Program:
See if your patients qualify
Explore the range of patients included in the SQUIRE trial
Help patients manage their skin and nails during treatment
Explore the results of the SQUIRE trial
Thoracic Treatment Talk:
Watch Ed Kim, MD, FACP, discuss Portrazza, a treatment option for your patients with metastatic squamous NSCLC
Learn more about the recommended dosing and administration of Portrazza
Learn more about dose modifications with Portrazza
Learn more about the incidence of dermatologic toxicities with Portrazza plus gemcitabine and cisplatin
View the incidence of electrolyte abnormalities with Portrazza plus gemcitabine and cisplatin
View the adverse reactions of Portrazza plus gemcitabine and cisplatin
High Unmet Need:
Review the unmet need in first-line squamous NSCLC
A multicenter, phase III trial in 1093 patients
Explore the results of the trial by using your login information at The Lancet®
Find out how Lilly PatientOne may provide financial assistance for eligible patients